Medical Microinstruments Raises $125 Million

The Series D round will fund global expansion of its Symani Surgical System and clinical research, including an Alzheimer's microsurgery study.

Updated on Nov. 1, 2026 in Alzheimer’s

Medical Microinstruments Raises $125 Million

Live Poll

Would you consider an experimental surgery for Alzheimer's if your doctor recommended it?

Medical Microinstruments raised $125 million in Series D financing, led by BioStar Capital. The company is also exploring microsurgical treatment for Alzheimer's disease through its REMIND study.

Why it matters

The funding will support global commercial expansion for the Symani Surgical System, improved patient access, and clinical research. Early human data on an Alzheimer's microsurgical approach represents a step toward a new treatment pathway for a disease affecting millions of Americans.

The figures come from company disclosures of its financing, installed base, and procedure volume, with no independent comparator provided. Long-term safety and efficacy of the Alzheimer's approach remain unverified pending broader studies.

The players

Medical Microinstruments (MMI)

MMI is the Jacksonville, Florida-based company that makes the Symani Surgical System for microsurgery.

BioStar Capital

BioStar Capital is the Naples, Florida-based investment firm that was the primary investor in MMI's Series D round.

The details

The Symani Surgical System is designed for microsurgery and used to repair tiny blood and lymphatic vessels, and it holds regulatory clearance in Europe and the U.S. The REMIND study is an early feasibility study in which the first patient underwent a microsurgical procedure addressing abnormalities in the deep cervical lymph node region.

May 2026: MMI announced the first REMIND patient had undergone a microsurgical procedure.
July 2026: The FDA authorized expansion of the REMIND trial to 15 participants.
Early November 2026: MMI announced the Series D financing.

Health Landscape

The Symani Surgical System, cleared for use in Europe and the U.S., is being extended from peripheral nerve and vessel repair into an Alzheimer's study. Whether microsurgical lymphatic-region intervention can become a recognized Alzheimer's approach will depend on the multicenter comparative trials the company has said are needed.

For people with Alzheimer's, this research is early-stage and not yet an available treatment option. Patients and families should continue to rely on established care plans while this microsurgical approach is studied further.

The takeaway

Early-stage research can open new treatment directions, but its promise must be confirmed through larger, comparative studies before it reaches patients. Readers should watch for those trial results rather than treat the approach as established.

What happens next

Broader, multicenter, and comparative studies of the REMIND approach are planned to evaluate clinical outcomes and seek additional indication approvals.